ASH 2025 | Nuvisertib + momelotinib in patients with R/R MF: Phase I/II findings

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the MPN Hub was pleased to speak with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the latest findings from the phase I/II study of nuvisertib in combination with momelotinib in patients with relapsed/refractory myelofibrosis (R/R MF)?

In this interview, Harrison discusses key findings from Arm 3 of the trial (NCT04176198), which enrolled patients who had been previously treated with a Janus kinase inhibitor (JAKi) other than momelotinib. The study aimed to identify the recommended phase II dose (RP2D) of nuvisertib when administered in combination with momelotinib, and to assess the safety, clinical activity (spleen volume reduction [SVR] and total symptom score [TSS] improvement), and pharmacokinetics and pharmacodynamic markers (including cytokines and bone marrow fibrosis).

This educational resource is independently supported by Sumitomo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.